目的:确定多囊卵巢综合征(PCOS)的女性与无PCOS的女性相比,SARS-COV-2检测阳性的发生率是否更高。在SARS-COV-2检测阳性的人中,评估PCOS诊断是否独立增加中度或重度疾病的风险.
方法:使用国家COVID队列协作(N3C)进行回顾性队列研究。
方法:成年非妊娠妇女(年龄18-65岁)在N3C注册,并进行了SARS-COV-2确诊的任何适应症检测。在18-49岁的女性和肥胖(体重指数>30kg/m2)的女性中进行了敏感性分析。
方法:暴露为N3C临床诊断代码和概念集确定的PCOS,它们是术语的汇编,诊断PCOS的实验室值和ICD代码。为了进一步捕获具有PCOS症状的患者,我们还包括那些具有多毛症和月经不调概念集的患者。
方法:与非PCOS队列相比,PCOS队列中SARS-COV-2检测呈阳性的几率和2019年中度或重度冠状病毒病(COVID-19)的几率。
结果:在我们研究的2,089,913名女性中,39,459人患有PCOS。在整个队列中,与未患有PCOS的女性相比,患有PCOS的女性SARS-CoV-2阳性的几率为OR0.98,95%CI0.97-0.98.疾病严重程度的几率为:轻度疾病:OR1.02,95%CI1.01-1.03中度疾病:OR0.99,95%CI0.98-1.00,重度疾病:OR0.99,95%CI0.99-1.00。COVID相关死亡率无差异(OR1.00,95%CI0.99-1.00)。这些发现在生殖年龄和肥胖生殖队列中相似。
结论:患有PCOS的女性SARS-COV-2检测呈阳性的可能性相似。在那些测试呈阳性的人中,与非PCOS队列相比,他们患中度或重度COVID-19疾病的可能性并不高.
结论:PCOS是一种与多种合并症相关的慢性疾病,包括心血管疾病和心理健康问题。虽然这些合并症也与COVID-19发病率相关,我们的研究结果表明,合并症本身而不是PCOS,驱动疾病严重程度的风险。
To determine whether women with polycystic ovary syndrome (PCOS) had a higher incidence of testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those without PCOS and evaluate whether PCOS diagnosis independently increased the risk of moderate or severe disease in those with positive SARS-CoV-2 test results.
Retrospective cohort study using the National COVID Cohort Collaborative (N3C).
National COVID Cohort Collaborative.
Adult nonpregnant women (age, 18-65 years) enrolled in the N3C with confirmed SARS-CoV-2 testing for any indication. Sensitivity analyses were conducted in women aged 18-49 years and who were obese (body mass index, ≥30 kg/m2).
The exposure was PCOS as identified by the N3C clinical diagnosis codes and concept sets, which are a compilation of terms, laboratory values, and International Classification of Diseases codes for the diagnosis of PCOS. To further capture patients with the symptoms of PCOS, we also included those who had concept sets for both hirsutism and irregular menses.
Odds of testing positive for SARS-CoV-2 and odds of moderate or severe coronavirus disease 2019 (COVID-19) in the PCOS cohort compared with those in the non-PCOS cohort.
Of the 2,089,913 women included in our study, 39,459 had PCOS. In the overall cohort, the adjusted odds ratio (aOR) of SARS-CoV-2 positivity was 0.98 (95% confidence interval [CI], 0.97-0.98) in women with PCOS compared to women without PCOS. The aORs of disease severity were as follows: mild disease, 1.02 (95% CI, 1.01-1.03); moderate disease, 0.99 (95% CI, 0.98-1.00); and severe disease, 0.99 (95% CI, 0.99-1.00). There was no difference in COVID-19-related mortality (aOR, 1.00; 95% CI, 0.99-1.00). These findings were similar in the reproductive-age and obese reproductive-age cohorts.
Women with PCOS had a similar likelihood of testing positive for SARS-CoV-2. Among those who tested positive, they were no more likely to have moderate or severe COVID-19 than the non-PCOS cohort. Polycystic ovary syndrome is a chronic condition associated with several comorbidities, including cardiovascular disease and mental health issues. Although these comorbidities are also associated with COVID-19 morbidity, our findings suggest that the comorbidities themselves, rather than PCOS, drive the risk of disease severity.